The outlook revision reflects Baxter’s continued volatility in operations and Moody’s Investors Service’s expectation that liquidity will remain constrained.
Moody’s also affirmed Baxter’s “Baa2” rating, affecting $41.8 million of debt. The rating affirmation is based on Baxter’s solid market position but remains constrained by Baxter’s small size.
More articles on healthcare finance:
231 hospitals inadvertently earned Medicare bonuses despite lower quality care
Harvard study finds consumer price shopping doesn’t lower healthcare costs
Fitch: As acquisitions continue, healthcare leverage increases
